A Phase 2/3 Trial of FG-4592 for Treatment of Anemia in Subjects With Lower Risk Myelodysplastic Syndrome

Trial Profile

A Phase 2/3 Trial of FG-4592 for Treatment of Anemia in Subjects With Lower Risk Myelodysplastic Syndrome

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs Roxadustat (Primary)
  • Indications Anaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors FibroGen
  • Most Recent Events

    • 02 Oct 2017 Status changed from planning to not yet recruiting.
    • 09 May 2017 According to a FibroGen media release, the company expects to initiate this trial in the fourth quarter of 2017.
    • 31 Mar 2017 According to a FibroGen media release, the company expects to initiate this trial in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top